← Eichor
Study identifier: NCT05329532 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer

Condition: Triple Negative Breast Cancer · Renal Cell Cancer · High Grade Ovarian Serous Adenocarcinoma  ·  Sponsor: Scancell Ltd

PhasePhase 1/Phase 2
Planned participants168
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The main objectives of this study are to assess the safety, tolerability, immunological activity, and preliminary efficacy of the Modi-1 Moditope vaccine, both as monotherapy and in combination with a checkpoint inhibitor (CPI) such as pembrolizumab or nivolumab with or without Ipilimumab (where these are standard of care in a non-neoadjuvant setting), in patients with advanced triple negative breast cancer (TNBC), advanced/unresectable human papillomavirus-negative squamous cell carcinoma of the head and neck (SCCHN), high grade serous ovarian carcinoma (HGSOC), or renal cell carcinoma (RCC). Modi-1 Moditope will also be investigated in the neoadjuvant setting for patients with SCCHN undergoing curative intent surgical resection in combination with pembrolizumab versus the Modi-1 alone.

This description comes directly from the study's public registry record.

Talk to the study team

Robert Miller  ·  +441865582690  ·  info@scancell.co.uk

Always discuss trial participation with your own doctor first.

Locations (16)

Brighton and Sussex University HospitalBrighton, Default, United KingdomActive Not Recruiting
Velindre Cancer CentreCardiff, Default, United KingdomRecruiting
Edinburgh Cancer Centre (NHS Lothian)Edinburgh, Default, United KingdomRecruiting
Royal Surrey NHS FoundationGuildford, Default, United KingdomRecruiting
Imperial College Healthcare NHS TrustLondon, Default, United KingdomActive Not Recruiting
Mount VernonLondon, Default, United KingdomRecruiting
University College London Hospital NHS Foundation TrustLondon, Default, United KingdomRecruiting
Christie NHS Foundation TrustManchester, Default, United KingdomRecruiting
Nottingham University Hospitals Cancer CentreNottingham, Default, United KingdomRecruiting
Lancashire Teaching Hospitals NHS Foundation TrustPreston, Default, United KingdomRecruiting
Sheffield Teaching Hospital NHS Foundation TrustSheffield, Default, United KingdomRecruiting
The Royal Marsden NHS Foundation TrustSutton, Default, United KingdomNot Yet Recruiting

+ 4 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05329532